We are proud to announce that AGILeBiotics has been awarded the European Soft Matter Infrastructure (EUSMI) grant from from the European Union’s Horizon 2020 research and innovation programme. EUSMI-H2020 provides the community of European soft-matter researchers with an open-access infrastructure as a platform to support and extend their research, covering characterization, synthesis, and modeling. Since November the DWI-Leibniz-Institute in Aachen (Germany) is engaged in the scale-up production of our antibiotic candidate Toframicin for pre-clinical development, i.e. efficacy and GLP-toxicity studies. Undoubtedly, this financial and infrastructural support will accelerate our pre-clinical development bringing Toframicin closer to the clinics.
About Toframicin: Toframicin is a semi-synthetic aminoglycoside with ultra-broad-spectrum activity against WHO’s priority pathogens, increased efficacy in vivo and in vitro, and increased therapeutic window. Toframicin is being developed for the treatment of patients with high-mortality rate infections, such as hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) and bloodstream infections (BSI). Click here to read more about Toframicin.
About EUSMI: EUSMI provides the community of European soft-matter researchers with an open-access infrastructure as a platform to support and extend their research, covering characterization, synthesis, and modeling.
The use of EUSMI installations is offered free of charge and financial contribution to related travel and accommodation costs is granted to successful applications from academia and from industry, thanks to financial support from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 731019 (EUSMI). Details of the application process and eligibility criteria are given in the terms of reference.
EUSMI aims to enhance the European competitiveness in soft-matter research and innovation through the integration and the extension of the scope of existing specialized infrastructures. A full suite of coherent key infrastructures and the corresponding expertise from 15 top-level institutions are combined within EUSMI, accessible to a broad community of researchers operating at different levels of the value chain, including SMEs and applied research.
Access is offered to infrastructures covering the full chain of functional soft-matter material research, ranging from advanced material characterization by a full suite of specialized experimental installations, including large-scale facilities, chemical synthesis of a full set of soft-matter materials, up-scaling of laboratory synthesis, to modeling by high-performance supercomputing. The existing infrastructure will be continuously improved and advanced by Joint Research Activity (JRA).
